Sold by: Proscia
Deployed on AWS
Sampling of Non-Small Cell Lung Cancer (NSCLC) solid tumor patient results from 2013 - 2023. Dataset includes digital pathology H&E and IHC images, 500+ gene NGS panel, FISH and other clinical data.
Overview
As an industry leader in enterprise pathology workflow software, we leverage our platform and network of labs to bridge the gap between patients and novel diagnostics through multi-modal, real-world data.
Proscia’s network unlocks access to otherwise siloed real-world data for discovery and diagnosis. We reduce time and cost by sourcing accurate, timely and high-quality datasets for even the rarest cancer biomarkers. Our curated datasets help drive innovation by uncovering personalized treatments that can transform patient outcomes.
Details
New
Introducing multi-product solutions
You can now purchase comprehensive solutions tailored to use cases and industries.
Features and programs
Financing for AWS Marketplace purchases
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
Pricing
This product is available free of charge. Free subscriptions have no end date and may be canceled any time.
Additional AWS infrastructure costs may apply. Use the AWS Pricing Calculator to estimate your infrastructure costs.
Dimensions summary
This listing uses a single pricing dimension. Product Access (Units) grants you access to the product at no cost. There are no tiers, instance sizes, or usage-based add-ons to compare. You subscribe under one flat structure that provides entry to the offering. Because this is a free listing, the unit does not scale to a charge as you add usage. This pathology AI product supports precision medicine work across research and diagnostic review.
Top-of-mind questions for buyers
This dimension grants you access to the product as a subscriber. It works as a single flat entry point with no cost attached. You receive access to the offering, which supports pathology work across research and diagnostic review. There are no seat counts, instances, or usage meters to track.
No. This is a free listing with one flat dimension. The unit does not scale to a charge as you add usage or users. There are no tiers, included amounts, or overage points that could trigger a cost change. Your subscription stays at no cost.
proscia.com
Helpful?
Vendor refund policy
Sample messages only
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA) .
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Additional details
You will receive access to the following data sets.
Data set name | Type | Historical revisions | Future revisions | Sensitive information | Data dictionaries | Data samples |
|---|---|---|---|---|---|---|
NSCLC_Sample Data | Last 1 revisions | No future revisions | Not included | Not included |
Resources
Vendor resources
Similar products
Machine Learning model to classify subjects’ susceptibility to lung cancer based on demographics, clinical measures and behavioral features.
Classifies non-Hodgkin’s Lymphoma subtypes
Prostate cancer is a type of cancer that develops in the prostate gland, a small walnut-shaped organ located below the bladder in the male reproductive system. The exact cause of prostate cancer is unknown.
Risk factors that may increase the likelihood of cancer are age (most common in men over 65), family history, race (african american men have a higher risk), and hormonal imbalance.
For this Lung Cancer dataset,four distinct cohorts have been prepared including (1) patients with confirmed nodules (2) patients with confirmed nodules and malignancy (3) patients with confirmed nodules and confounders (4) normal (negative results) for control group.